PTHS — Pelthos Therapeutics Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 1919246 ·
Last close
$6.84
Market Cap
$26.89M
52W High
$32.51
52W Low
$6.76
ADV30
64,295
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 15,395,000 | 10,287,000 | -9,693,000 | -7,895,000 | 128,817,000 | 17,690,000 | 135,003,000 |
| Jun 2026 | 15,603,000 | 2,774,000 | -17,323,000 | -23,417,000 | 137,356,000 | 24,192,000 | 138,857,000 |
| Mar 2026 | 10,906,000 | 5,594,000 | -13,088,000 | -25,073,000 | 145,378,000 | 31,976,000 | 110,276,000 |
| Dec 2025 | 9,389,000 | 4,999,000 | -12,003,000 | -21,664,000 | 130,397,000 | 17,973,000 | 91,516,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-32,206,000
Investing CF
$2,505,000
Financing CF
$44,369,000
CapEx
$-256,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-23.10
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-121,179,000
Inventory
$21,471,000
Receivables
$13,413,000
ST Investments
—
EBIT TTM
$-76,646,000
Pretax Income TTM
$-84,971,000
Interest Exp TTM
$8,325,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$43,304,000
EBITDA
—
Free Cash Flow
$-36,573,780
Enterprise Value
$77,400,808
Total Cash
$24,192,000
Total Debt
$73,109,000
Shares Out
3,930,709
Trailing EPS
$-23.86
Book Value
$-0.40
ROE
-333.8%
ROA
-50.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 16,795,000 | -32,430,000 | -43,319,000 | 130,397,000 | 91,516,000 | 38,881,000 | -22,590,000 |
| Dec 2024 | 0 | -7,571,000 | -7,955,000 | 1,369,000 | 4,083,000 | -2,714,000 | -5,792,000 |
| Dec 2023 | 0 | -6,862,284 | -7,380,793 | 96,391 | 6,540,943 | -6,444,552 | -981,031 |
| Dec 2022 | 0 | -2,318,159 | -2,458,589 | 55,074 | 3,761,611 | -3,706,537 | -1,567,149 |
TTM Snapshot
Revenues TTM
$43,304,000
NetIncome TTM
$-71,557,450
OpCashFlow TTM
—
Assets (Latest)
$137,356,000
Forward EPS
$-6.56
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LONA | LeonaBio, Inc. | $26.00M | $2.76 | — |
| SAEN | Genenta Science S.p.A. | $27.82M | $0.58 | — |
| EVAX | Evaxion A/S | $25.08M | $2.78 | — |
| INMB | Inmune Bio, Inc. | $29.72M | $0.96 | — |
| MGX | Metagenomi Therapeutics, Inc. | $23.86M | $0.63 | — |
News headlines (Yahoo Finance, 1h cache)
Pelthos Therapeutics (PTHS) Stock Sees Fair Value Cut As Analysts Rework Launch And Merger Risks
2026-11-16 15:15 · Yahoo
Pelthos Therapeutics Inc. Q3 2026 Earnings Call Summary
2026-11-13 01:35 · Yahoo
Pelthos (PTHS) Q3 2026 Earnings Call Transcript
2026-11-13 00:29 · Yahoo
Pelthos Therapeutics Inc. (PTHS) Reports Q3 Loss, Lags Revenue Estimates
2026-11-12 12:25 · Yahoo
Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 12:00 · Yahoo
Pelthos Therapeutics to Report Third Quarter 2026 Financial Results on November 12, 2026
2026-11-04 21:05 · Yahoo
Pelthos and Castle Creek plan merger to target skin diseases
2026-11-02 10:55 · Yahoo
Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin
2026-10-30 13:09 · Yahoo
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%
2026-10-06 12:00 · Yahoo
Pelthos (PTHS) Q2 2026 Earnings Call Transcript
2026-08-20 13:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.